- Home
- MCBS vs ZYME Comparison
MCBS vs ZYME Comparison
Compare MCBS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCBS
- ZYME
- Stock Information
- Founded
- MCBS 2006
- ZYME 2003
- Country
- MCBS United States
- ZYME United States
- Employees
- MCBS N/A
- ZYME N/A
- Industry
- MCBS Major Banks
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- MCBS Finance
- ZYME Health Care
- Exchange
- MCBS Nasdaq
- ZYME Nasdaq
- Market Cap
- MCBS 745.5M
- ZYME 846.1M
- IPO Year
- MCBS 2019
- ZYME 2017
- Fundamental
- Price
- MCBS $27.94
- ZYME $11.43
- Analyst Decision
- MCBS Hold
- ZYME Buy
- Analyst Count
- MCBS 1
- ZYME 7
- Target Price
- MCBS $34.00
- ZYME $19.50
- AVG Volume (30 Days)
- MCBS 26.0K
- ZYME 449.0K
- Earning Date
- MCBS 07-18-2025
- ZYME 05-08-2025
- Dividend Yield
- MCBS 3.29%
- ZYME N/A
- EPS Growth
- MCBS 30.91
- ZYME N/A
- EPS
- MCBS 2.58
- ZYME N/A
- Revenue
- MCBS $143,775,000.00
- ZYME $93,384,000.00
- Revenue This Year
- MCBS $16.00
- ZYME $34.23
- Revenue Next Year
- MCBS $31.75
- ZYME $68.78
- P/E Ratio
- MCBS $10.83
- ZYME N/A
- Revenue Growth
- MCBS 19.70
- ZYME 85.05
- 52 Week Low
- MCBS $23.27
- ZYME $8.21
- 52 Week High
- MCBS $36.15
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- MCBS 47.10
- ZYME 45.92
- Support Level
- MCBS $27.79
- ZYME $11.46
- Resistance Level
- MCBS $28.47
- ZYME $11.81
- Average True Range (ATR)
- MCBS 0.50
- ZYME 0.59
- MACD
- MCBS -0.15
- ZYME -0.05
- Stochastic Oscillator
- MCBS 26.69
- ZYME 27.62
About MCBS MetroCity Bankshares Inc.
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.